ONESOURCE Onesource Specialty Pharma Q1 FY27 results (Apr–Jun 2026) and concall
Onesource Specialty Pharma Limited delivered a strong Q1 FY27, with significant revenue and EBITDA growth fueled by semaglutide commercialization and new contracts. The company is actively expanding its manufacturing capacity, with new lines coming online and a substantial biologics pipeline. Despite temporary supply disruptions and geopolitical headwinds, management remains confident in achieving its FY28 targets, supported by a diverse customer base and strategic capacity additions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 37.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 393 | 426 | 327 | 376 | 290 −26% | 428 +0% | 449 +37% |
| EBITDA | 142 | 183 | 88 | 106 | 17 −88% | 92 −50% | 123 +40% |
| Net profit | -69 | 98 | 0 | 10 | -89 −29% | 5 −95% | 25 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
